United Immunity raises ¥2.2B ($13.9M) in private equity and debt financing led by ITOCHU Corporation and others to advance UI-102 program for solid tumors and fibrotic diseases.
Amount Raised
$13.9 Million
Round Type
Debt Financing
Investors
Description
United Immunity, a Tokyo-based clinical-stage biotechnology company, raised ¥2.2B (approximately USD 13.9M) comprising ¥1.8B in private equity financing and ¥0.4B in debt financing. The funding was backed by a consortium of 13 investors including ITOCHU Corporation, Ono Venture Investment, and multiple life science investment partnerships. The company will use the proceeds to accelerate R&D of its lead program UI-102 and in vivo macrophage engineering programs targeting solid tumors and fibrotic diseases, while expanding R&D capabilities globally.
Quick answer
United Immunity raised $13.9 Million in a Debt Financing round, dated September 24, 2026. Investors: Utec 5 Investment Limited Partnership, Itochu Corporation, Mizuho Life Science No. 1 Investment Limited Partnership, Mufg Life Science No. 2 Investment Limited Partnership, Miyako Kyoto University Innovation No. 3 Investment Limited Partnership, The Joyo Bank, Ltd., Aozora Hybrid No. 3 Investment Limited Partnership and Kuc No. 1 Investment Limited Partnership. United Immunity is based in Tokyo, Tokyo, Japan.
- How much did United Immunity raise?
- United Immunity raised $13.9 Million in a Debt Financing round on September 24, 2026.
- Who invested in United Immunity?
- Utec 5 Investment Limited Partnership, Itochu Corporation, Mizuho Life Science No. 1 Investment Limited Partnership, Mufg Life Science No. 2 Investment Limited Partnership, Miyako Kyoto University Innovation No. 3 Investment Limited Partnership, The Joyo Bank, Ltd., Aozora Hybrid No. 3 Investment Limited Partnership and Kuc No. 1 Investment Limited Partnership are named as investors in this round.
- What does United Immunity do?
- United Immunity is a Tokyo-based clinical-stage biotechnology company developing a proprietary Myeloid Targeting Platform designed to selectively target and program macrophages and dendritic cells using pullulan-based..
- Where is United Immunity based and how big is it?
- United Immunity is based in Tokyo, Tokyo, Japan. Fundz records about 17 employees.
- Who are the decision-makers at United Immunity?
- Fundz holds 2 contacts at United Immunity, including the Chief Medical Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as United Immunity that raised within 45 days of this round, from Fundz verified event records.
- BioVie raised $4.7M (Post-IPO Equity) on November 6, 2026.
- Anaheim Bio raised $45M (Series A) on November 5, 2026.
- Alethio raised $90M (Series A) on November 5, 2026.
- Emvena Therapeutics raised an undisclosed amount (Seed) on November 4, 2026.
- MyoPax raised an undisclosed amount (Pre-Seed) on November 4, 2026.
- Biograil raised $22M on November 4, 2026.
Who to call at United Immunity, and when
A new round usually means United Immunity is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day United Immunity raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at United Immunity, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at United Immunity. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment United Immunity raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
United Immunity raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.